References
- Arnulfo G., Mortola G. P., Buluggiu G., Frascio M., Di Somma C., Berti Riboli E. Studio clinic0 sull'azione della Somatostatina (GH-RIF) sull'attivita dello sfintere di. Oddi. G. Chir 1984; 5: 76–781. Arnulfo G., Mortola G. P., Buluggiu G., Frascio M., Di Somma C., Berti Riboli E. Studio clinic0 sull'azione della Somatostatina (GH-RIF) sull'attivita dello sfintere di. Oddi. G. Chir 1984; 5: 76–78
- Jorpes J. E. The isolation and chemistry of secretin and cholecystokinin. Gastro-enterology 1968; 55: 157–1642. Jorpes J. E. The isolation and chemistry of secretin and cholecystokinin. Gastro-enterology 1968; 55: 157–164
- Kawazu M., Kahno T., Saito S., Tanaki H. 5-hydroxy-3-piperidylidene methane derivatives as spasmolytics. J. Med. Chem 1972; 15: 914–9183. Kawazu M., Kahno T., Saito S., Tanaki H. 5-hydroxy-3-piperidylidene methane derivatives as spasmolytics. J. Med. Chem 1972; 15: 914–918
- Lin T. M. Actions of gastro-intestinal hormones and related peptides on the motor function of the biliary tract. Gastroenterology 1975; 9: 1006–10224. Lin T. M. Actions of gastro-intestinal hormones and related peptides on the motor function of the biliary tract. Gastroenterology 1975; 9: 1006–1022
- Omata S., Shimizo N. Clinical trials of timepidium bromide (SA-504) for the treatment of abdominal pain in gastro-intestinal diseases: a double-blind controlled trial. Ctin. Evaluation 1974; 2: 212–2215. Omata S., Shimizo N. Clinical trials of timepidium bromide (SA-504) for the treatment of abdominal pain in gastro-intestinal diseases: a double-blind controlled trial. Ctin. Evaluation 1974; 2: 212–221
- Tamaki H., Tanaka M., Murata S., Harigaya S., Kiyomoto A. Pharmacological properties of a new anticholinergic agent,1, l-dimethyl-5-methoxy-3-(dithien-2-ylrnethylene) piperidinium bromide (SA-504). Jpn. J. Pharmacol 1972; 22: 685–6996. Tamaki H., Tanaka M., Murata S., Harigaya S., Kiyomoto A. Pharmacological properties of a new anticholinergic agent,1, l-dimethyl-5-methoxy-3-(dithien-2-ylrnethylene) piperidinium bromide (SA-504). Jpn. J. Pharmacol 1972; 22: 685–699
- Tamazawa Y., Oriso A., Kobayashi N., Eno G. The experimental study of effects of SA-504 on biliary motility and pancreatic secretion. Clin. Report 1975; 9: 577–5827. Tamazawa Y., Oriso A., Kobayashi N., Eno G. The experimental study of effects of SA-504 on biliary motility and pancreatic secretion. Clin. Report 1975; 9: 577–582
- Weiner N. Atropine, scopolamine, and related antimuscarinic drugs. “The Pharmacologic Basis of Therapeutics”, A. 0 GoodmanGilman, L. S. Goodman, A. 0 Gilman. Macmillan, New York 1980; 120–137.8. Weiner N. Atropine, scopolamine, and related antimuscarinic drugs. “The Pharmacologic Basis of Therapeutics”, A. 0 GoodmanGilman, L. S. Goodman, A. 0 Gilman. Macmillan, New York 1980; 120–137.
- Yoneda M., Tashiro T. Clinical experience with a new anticholinergic agent SA-504. Jpn. Arch. Int. Med 1972; 19: 419–4239. Yoneda M., Tashiro T. Clinical experience with a new anticholinergic agent SA-504. Jpn. Arch. Int. Med 1972; 19: 419–423